Quantum Biopharma ( (TSE:QNTM) ) has issued an announcement.
On March 27, 2025, Quantum BioPharma announced the appointment of Terry Lynch to its board of directors, succeeding Dr. Sanjiv Chopra, who will continue as an advisor. Lynch, known for his efforts against stock market manipulation and naked short selling, brings extensive experience in raising capital and biotech investment. His appointment is expected to bolster Quantum’s strategic initiatives and enhance its market positioning, particularly in addressing stock market challenges.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is advancing its lead compound, Lucid-MS, aimed at treating multiple sclerosis by preventing and reversing myelin degradation. Quantum BioPharma also holds a strategic investment portfolio and retains a significant stake in Celly Nutrition Corp., which markets the OTC version of its product, unbuzzd.
YTD Price Performance: 70.34%
Average Trading Volume: 2,628,420
Technical Sentiment Signal: Buy
Current Market Cap: $11.42M
See more insights into QNTM stock on TipRanks’ Stock Analysis page.